February 6, 2019

No deal brexit’s impact on the pharmaceutical and medical devices industries: guidance from the ema and the european commission

On January 15, 2019, the UK House of Commons rejected the withdrawal agreement reached by Theresa May and the EU after a long and exhausting negotiation period of almost 2 years. On March 29, 2019, the UK will officially leave the EU unless Article 50 of the Treaty on European Union is delayed or revoked. A delay in the UK leaving the EU seems to be the most reasonable and conservative option at this stage, but the future is profoundly uncertain and a No Deal Brexit is becoming an increasingly more realistic possibility by the day.

In relation to the above, the European Medicines Agency and the European Commission are providing guidance on Brexit for pharmaceutical companies, including launching a dedicated page on their website.

On February 1, 2019, the European Commission published an updated Q&A document on the topic of the UK’s withdrawal from the EU with regard to industrial products, including medical devices, and medical products for human and veterinary use, which can be viewed at the following links:

–          Medical products for human and veterinary use

–          Industrial products, including medical devices

These FAQs address the scenario in which the UK will leave the EU without any transition period or without any other arrangements being put in place, and therefore having a potentially disruptive impact on businesses. In this case, the UK will immediately become a third country from the EU’s perspective.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
June 30, 2023
Payback for medical devices: on June 28 Italian parliament approved the Law which, among other things, extends the deadline for the payment of the amount reduced by 52% from June 30th to Jul...
June 20, 2023
Clinical investigations on medical devices: four ministerial decrees setting out procedures for submitting applications/notifications and requirements for facilities and assessing persons, i...
March 20, 2023
Today, Regulation (EU) 2023/607 extending the transitional provisions for the placing on the market and putting into service of certain medical devices and in vitro diagnostic medical device...
Search by...
Follow us on
Follow us on